Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-141 in healthy adults
NCT06148181Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-141 in idiopathic pulmonary fibrosis (IPF) (8 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time to Cmax and 7 more. Started Jan 2024; status: completed.
02
Drugs
ABBV-141
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06148181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06148181.